Literature DB >> 29289256

The Complexity of Characteristics, Diagnoses and Treatment of Older Patients With Pulmonary Hypertension.

Hawa Edriss1, Kavitha Selvan2, Tatiana Denega2, Terrance Rodrigues2, Victor Test3, Kenneth Nugent4.   

Abstract

BACKGROUND: Older patients with pulmonary hypertension (PH) are more likely to have complex comorbidity than younger patients with pulmonary arterial hypertension (PAH). The best approach to the evaluation and management of these patients is unclear.
METHODS: We, retrospectively, reviewed the clinical records of patients older than 60 years referred for evaluation for PAH. We recorded patient demographics, comorbidity, functional classification (FC), right heart catheterization data, echocardiographic data, chest radiographic images and pulmonary function results. We recorded the final diagnoses according to World Health Organization (WHO) subgroups and treatment outcomes based on changes in FC.
RESULTS: Ninety-seven records were reviewed in detail. The mean age was 71.2 ± 7.5 years with 66% women. Cardiovascular disease was the most frequent comorbidity. Mean PA pressure by catheterization was 39.5 ± 12.2mmHg (n = 65). The overall distribution after evaluation included 21 (21.6%) Group 1, 35 (36.1%) Group 2, 16 (16.5%) Group 3, 18 (18.6%) mixed Group 2 and 3, 6 (6.2%) Group 4 and 1 (1%) Group 5 patients. Group 1 patients were treated with PAH specific drug, and 12 patients had an improvement in FC with treatment.
CONCLUSIONS: Older patients with suspected PH often have significant cardiovascular and respiratory comorbidity. Comprehensive evaluations are needed to determine the severity of PH and associated diseases and to initiate treatment focused on FC. Patients in WHO Group 2 and mixed Group 2 and 3 were frequently identified and constituted a diagnostic and treatment challenge in this study. Older patients with PAH may benefit from PAH specific drugs. Published by Elsevier Inc.

Entities:  

Keywords:  Older patients; Pulmonary hypertension; Right heart catheterization; WHO classification

Mesh:

Substances:

Year:  2017        PMID: 29289256     DOI: 10.1016/j.amjms.2017.07.008

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  2 in total

1.  The Utility of Brain Natriuretic Peptide in Patients Undergoing an Initial Evaluation for Pulmonary Hypertension.

Authors:  Sanjana Rao; Benjamin Daines; Omid Hosseini; Victor Test; Kenneth Nugent
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-05-02

2.  Baseline Ratio of Soluble Fas/FasL Predicts Onset of Pulmonary Hypertension in Elder Patients Undergoing Maintenance Hemodialysis: A Prospective Cohort Study.

Authors:  Xiao-Han Ding; Xiaoliang Chai; Jin Zheng; Hong Chang; Wenxue Zheng; Shi-Zhu Bian; Ping Ye
Journal:  Front Physiol       Date:  2022-03-01       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.